What Teva-Citalopram Treats: Main Uses and Benefits

Teva-Citalopram is applicable within clinical settings that involve acute or disruptive symptom patterns, such as Major Depressive Disorder (MDD). It is relevant for managing symptoms across conditions associated with acute or disruptive episodes, including Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD). It helps address groups of symptoms that may appear suddenly or intensify over time, including persistent low mood, loss of pleasure, and feelings of excessive guilt.

The medication is applied in settings marked by temporary physiological imbalance where additional symptomatic support is needed, and may be part of symptomatic management for both acute and long-term phases. It may assist with maintaining a sense of stability when symptoms are more noticeable, helping patients cope more steadily with symptom fluctuations.

“It is relevant for managing symptoms that interfere with daily comfort, and may assist with easing the overall symptom load.”

Quick Fact: Supports Functional Comfort

Teva-Citalopram is applied when symptoms create noticeable functional strain, contributing to improved comfort during periods of heightened symptoms.

Who Can and Cannot Use Teva-Citalopram?

Eligibility for Teva-Citalopram is strictly defined by regulatory documents, outlining populations that are permitted, restricted, or absolutely prohibited from use.

---

Absolute Contraindications

Use is strictly prohibited in patients with known hypersensitivity to escitalopram or citalopram. The medicine is also contraindicated for patients taking Monoamine Oxidase Inhibitors (MAOIs) or pimozide, as well as any medicinal products known to prolong the QT interval. Patients with pre-existing known QT interval prolongation or congenital long QT syndrome are formally excluded.

---

Population and Organ Function Restrictions

Restrictions apply to several populations. Older adults and patients with hepatic impairment are subject to a maximum recommended dose restriction. Caution is formally required for patients with severe renal impairment, a history of seizures or mania, angle-closure glaucoma, and those with an increased bleeding risk.

---

Age and Reproductive Status

Age-related eligibility varies by indication: use is not established for children under 12 years for Major Depressive Disorder or under 7 years for Generalized Anxiety Disorder. Furthermore, European regulatory guidance generally advises it is not recommended for the treatment of depression in adolescents under 18. During pregnancy and lactation, official guidance recommends that use be conditional, only proceeding if the potential benefit justifies the potential risk.

Interactions with other medicines and products

Regulatory documents define two primary classifications for Escitalopram interactions: prohibited combinations and substances requiring caution due to altered risk or exposure.

Contraindicated Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration with non-selective, irreversible MAOIs is prohibited due to the risk of Serotonin Syndrome. A mandatory 14-day washout period is required between discontinuing an MAOI and starting Escitalopram, or vice-versa.
• Pimozide and other QT-Prolonging Medicines: Prohibited due to the documented potential for additive effects resulting in QT-interval prolongation.

Pharmacodynamic and Pharmacokinetic Interactions

• Other Serotonergic Drugs: Combining with other serotonergic medicines, such as Triptans or Tramadol, carries a documented risk for developing Serotonin Syndrome.
• Drugs that Interfere with Hemostasis: Co-administration with agents like NSAIDs, Aspirin, or Warfarin increases the officially noted risk of abnormal bleeding.
• CYP Enzyme Inhibitors: Escitalopram is primarily metabolized by CYP enzymes. Concomitant use with inhibitors (e.g., Cimetidine) may cause a documented increase in Escitalopram plasma concentration.
• Alcohol/Food: Food does not affect absorption. Although specific clinical trials did not show potentiation of cognitive impairment with alcohol, regulatory guidance states that co-use of alcohol is not advised.

Caution is noted for use in populations such as those with hepatic impairment, where altered metabolism may affect drug clearance.

Selective Inhibition of Serotonin Reuptake

The primary mechanism involves the inhibition of the Serotonin Transporter (SERT) (SLC6A4) protein in the Central Nervous System. By blocking this transporter, Escitalopram prevents the nerve cell from reabsorbing the neurotransmitter Serotonin (5-HT), resulting in an acute, localized increase in the extracellular concentration of 5-HT within the synaptic cleft.

Time-Dependent Neurochemical Homeostasis

The initial molecular action triggers a crucial neuroadaptive process that unfolds over several weeks: the sustained increase in 5-HT causes the desensitization and downregulation of inhibitory presynaptic 5-HT1A autoreceptors. This slow, regulatory change removes a key inhibitory constraint, allowing for a sustained, functional potentiation of serotonergic activity that ultimately establishes a more stable neurochemical state.

Modulation of Neuronal Plasticity Pathways

As a long-term consequence of the enhanced serotonergic activity, the mechanism extends to influencing pathways associated with neuronal plasticity. This includes modulating factors like Brain-Derived Neurotrophic Factor (BDNF), influencing the processes related to neuronal structural integrity and contributing to the persistent, regulated state within key signaling pathways.

Administration and Dosing Schedule

Teva-Citalopram is administered via the oral route and is available as a film-coated tablet or an oral solution (1 mg per mL). Tablets of 10 mg and 20 mg are scored, allowing for division for administration flexibility or controlled dose reduction. The oral solution form requires the bottle to be shaken and the dose to be accurately measured using a marked device prior to intake.

The medication is administered once daily and may be taken with or without food. For most adults, the starting dose is typically 10 mg. This dose can be adjusted upward to a maximum of 20 mg once daily, but this adjustment occurs after a minimum of one week to allow for proper titration and monitoring.

---

Specific Population and Course Duration

Guidelines are established for distinct use in certain populations. The recommended maximum dosage for older adults (aged 65 years and older) is typically limited to 10 mg once daily. Dosing schedules are also defined for pediatric use, starting at 10 mg once daily for Major Depressive Disorder in patients aged 12 years and older and Generalized Anxiety Disorder in patients aged 7 years and older.

Treatment follows a structured course that includes both an acute phase and a prolonged maintenance phase (often at least 6 months for MDD consolidation). When discontinuing treatment, a procedural gradual dose reduction (tapering) is necessary over a period of at least one to two weeks, as abrupt cessation is not recommended. If a dose is missed, the next scheduled dose is taken at the usual time without attempting to double the dose.

Evidence for Use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

The clinical evidence for Teva-Citalopram (Escitalopram) is primarily derived from short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms are measured in adults with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). For MDD, researchers monitored outcomes related to functional imbalance, such as changes in depressive symptom severity, and assessed whether patients met pre-defined criteria for response or remission. Similar short-term RCTs, typically lasting 8 to 12 weeks, were evaluated for GAD, examining changes in anxiety symptom severity and patient response rates.

Evidence for Panic Disorder and Social Anxiety Disorder

For conditions involving periods of heightened symptoms, specifically Panic Disorder and Social Anxiety Disorder, the research structure is based on short-term clinical trials. These studies examined specific outcomes such as the reduction in the frequency and severity of panic attacks and the monitoring of fear and avoidance behaviors. The overall number of dedicated clinical trials for these conditions is limited when compared to the research base for MDD and GAD.

Long-Term Outcomes and Research Gaps

The question of sustained outcomes was explored in maintenance trials, which observed patients for up to one year to examine outcomes related to the prevention of relapse. However, long-term effects are not fully established for periods extending over multiple years, and the clinical research record largely relies on extrapolation from shorter maintenance periods. Research in adolescents (12–17 years) for MDD and GAD has been conducted, but findings were mixed across studies. Key limitations in the overall evidence base include limited follow-up durations in acute trials and comparative evidence lacking against the full range of other treatments.

Key Studies & References

1. Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial
2. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]
3. A Review of Escitalopram and Citalopram in Child and Adolescent Depression

Common questions about Teva-Citalopram (FAQ)

Q: What is Teva-Citalopram, and how does it work?

A: Teva-Citalopram contains the active ingredient citalopram, which is a type of antidepressant medication. It belongs to a group of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs).

It is thought to work by helping to restore the balance of a natural substance called serotonin in the brain. Serotonin is a neurotransmitter involved in regulating mood. By inhibiting the reuptake of serotonin by nerve cells, Teva-Citalopram increases the amount of available serotonin in the space between nerve cells, which helps improve mood.

Q: What conditions is Teva-Citalopram used to treat?

A: Teva-Citalopram is used to treat major depressive disorder (MDD) in adults. It may also be used to treat other conditions as determined by a healthcare provider.

Q: How should I take Teva-Citalopram?

A: You should take Teva-Citalopram exactly as instructed by your doctor. The tablets should be swallowed whole with a drink of water and should not be chewed. Teva-Citalopram can be taken with or without food, and it is generally recommended to take it once daily, preferably at the same time each day.

Do not change your dose or stop taking the medication abruptly unless your doctor advises you to do so. Abruptly stopping the medication can lead to withdrawal symptoms.

Q: How long does it take for Teva-Citalopram to start working?

A: It is important to know that Teva-Citalopram may take several weeks to start working, and improvement may be gradual. You should continue to take the medication as prescribed even if you do not feel better right away.

Your doctor may tell you to continue to take Teva-Citalopram for several months after you start feeling better to maintain the effect.

Q: What should I do if I miss a dose of Teva-Citalopram?

A: If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a forgotten dose.

If you are unsure what to do, contact your doctor or pharmacist for advice.

Q: What are the common side effects of Teva-Citalopram?

A: Teva-Citalopram may cause unwanted effects, which are often mild and may disappear after a few days. Common side effects may include:

• Fatigue or sleepiness (somnolence)
• Dry mouth
• Increased sweating
• Shakiness (tremor)
• Nausea
• Diarrhea
• Ejaculation disorder (in men)
• Upper respiratory tract infection

If side effects are troublesome or persistent, or if you develop any other unusual side effects, consult your doctor.

Q: Are there any serious warnings I should be aware of?

A: Yes. Patients of all ages who start on antidepressant therapy, including Teva-Citalopram, should be monitored closely for clinical worsening, suicidal thoughts or behavior (suicidality), or unusual changes in behavior, especially during the first few months of treatment or when the dose is adjusted. Depression itself is associated with an increased risk of suicide.

Other important warnings include:

• Serotonin Syndrome: A potentially life-threatening condition that can occur when Teva-Citalopram is taken with other medicines that affect serotonin levels. Symptoms can include agitation, hallucinations, coma, rapid heart rate, fluctuating blood pressure, dilated pupils, fever, and muscle rigidity.
• Increased Risk of Bone Fractures: Taking Teva-Citalopram may increase the risk of breaking a bone, especially in elderly patients or those with osteoporosis. Extra care should be taken to avoid falls.
• Interactions: Do not use Teva-Citalopram if you are currently taking or have recently taken a monoamine oxidase inhibitor (MAOI), as this combination can lead to serious side effects.

Official Storage and Disposal Instructions

Teva-Citalopram (Citalopram Hydrobromide) must be stored according to specific regulatory guidelines to maintain its integrity and ensure environmental safety.

Storage Requirements	Details
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Handling/Protection	Keep the container tightly closed and protect from heat. Store securely, out of the reach of children.

Official Disposal Rules:

The most appropriate method for disposing of unused or expired Teva-Citalopram is to use a drug take-back program or a mail-back service where available. If no take-back program is available, the medication should be mixed with an undesirable substance (such as dirt or used coffee grounds) in a sealed container and placed in the household trash. It is officially classified as an Environmentally Hazardous Substance, and it must not be flushed down the toilet or allowed to enter water systems.